MA23780A1 - Quinazolinones 2, 8 disubstitues - Google Patents

Quinazolinones 2, 8 disubstitues

Info

Publication number: MA23780A1
Authority: MA; Morocco
Prior art keywords: disubstitues; quinazolinones
Prior art date: 1995-01-19

Application number

MA24135A

Other languages

English (en)

Inventor

Perzborn Elisabeth

Schramm Matthias

Bischoff Erwin

Schutz Helmuth

Niewohner Ulrich

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-19

Filing date

1996-01-18

Publication date

1996-10-01

1996-01-18 Application filed by Bayer Ag filed Critical Bayer Ag

1996-10-01 Publication of MA23780A1 publication Critical patent/MA23780A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3

MA24135A 1995-01-19 1996-01-18 Quinazolinones 2, 8 disubstitues MA23780A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19501481A DE19501481A1 (de)	1995-01-19	1995-01-19	2,8-Disubstituierte Chinazolinone

Publications (1)

Publication Number	Publication Date
MA23780A1 true MA23780A1 (fr)	1996-10-01

Family

ID=7751829

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA24135A MA23780A1 (fr)	1995-01-19	1996-01-18	Quinazolinones 2, 8 disubstitues

Country Status (32)

Country	Link
US (1)	US5721238A (fr)
EP (1)	EP0722937A1 (fr)
JP (1)	JPH08253457A (fr)
KR (1)	KR960029325A (fr)
CN (1)	CN1134417A (fr)
AR (1)	AR006738A1 (fr)
AU (1)	AU704102B2 (fr)
BG (1)	BG100293A (fr)
BR (1)	BR9600148A (fr)
CA (1)	CA2167345A1 (fr)
CO (1)	CO4700522A1 (fr)
CZ (1)	CZ16796A3 (fr)
DE (1)	DE19501481A1 (fr)
EE (1)	EE9600019A (fr)
FI (1)	FI960227A (fr)
HR (1)	HRP960004A2 (fr)
HU (1)	HUP9600114A3 (fr)
IL (1)	IL116770A (fr)
IN (1)	IN184956B (fr)
MA (1)	MA23780A1 (fr)
NO (1)	NO307513B1 (fr)
NZ (1)	NZ280831A (fr)
PE (1)	PE66696A1 (fr)
PL (1)	PL312352A1 (fr)
RO (1)	RO117451B1 (fr)
RU (1)	RU2158733C2 (fr)
SG (1)	SG34377A1 (fr)
SK (1)	SK7796A3 (fr)
SV (1)	SV1996000005A (fr)
TR (1)	TR199600029A2 (fr)
YU (1)	YU1496A (fr)
ZA (1)	ZA96397B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2238283C (fr)	1997-05-30	2002-08-20	Cell Pathways, Inc.	Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
US5858694A (en) *	1997-05-30	1999-01-12	Cell Pathways, Inc.	Method for identifying compounds for inhibition of cancerous lesions
US20020025969A1 (en) *	1997-07-09	2002-02-28	Wolf-Georg Forssmann	Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6410584B1 (en)	1998-01-14	2002-06-25	Cell Pathways, Inc.	Method for inhibiting neoplastic cells with indole derivatives
US6132757A (en)	1998-05-01	2000-10-17	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6194433B1 (en) *	1998-10-05	2001-02-27	Neal R. Cutler	Sexual dysfunction in females
US6110489A (en) *	1998-05-01	2000-08-29	Cutler; Neal R.	Use of quinolines and quinolones to treat male erectile dysfunction
US6132753A (en) *	1998-05-01	2000-10-17	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en)	2000-06-19	2002-07-30	Neal R. Cutler	Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en)	1999-03-04	2001-02-13	Neal R. Cutler	Use of cilostazol for treatment of sexual dysfunction
US6130053A (en) *	1999-08-03	2000-10-10	Cell Pathways, Inc.	Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en)	1998-10-15	2001-03-13	Cell Pathways, Inc.	Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) *	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en)	1998-11-20	2001-02-13	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en)	1998-11-23	2002-04-09	Cell Pathways, Inc.	Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) *	1998-11-24	2000-06-20	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) *	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en)	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en)	1999-01-29	2000-02-15	Cell Pathways, Inc.	Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) *	1999-02-19	2000-02-01	Cell Pathways, Inc.	Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6303135B1 (en)	1999-07-08	2001-10-16	Neal R. Cutler	Use of quinolines and quinolones to treat male erectile dysfunction
US6555547B1 (en)	2000-02-28	2003-04-29	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en)	2000-03-03	2003-05-27	Cell Pathways, Inc	Method for screening compounds for the treatment of neoplasia
US7501409B2 (en) *	2000-09-06	2009-03-10	Mitsubishi Tanabe Pharma Corporation	Preparations for oral administration
US6562838B2 (en) *	2001-01-26	2003-05-13	R. T. Alamo Ventures I, L.L.C.	Treatment of cardiovascular disease with quinolinone enantiomers
NZ527585A (en)	2001-02-15	2005-04-29	Tanabe Seiyaku Co	Tablets quickly disintegrated in oral cavity
CA2462149C (fr) *	2001-11-30	2010-06-22	Pfizer Products Inc.	Procedes de preparation de derives bicycliques substitues utilise pour traiter la croissance cellulaire anormale
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en)	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en)	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
AU2003250701A1 (en)	2002-07-31	2004-02-16	Wayne R. Danter	Protein tyrosine kinase inhibitors
ES2298563T3 (es)	2002-10-09	2008-05-16	Critical Outcome Technologies, Inc.	Inhibidores de proteinas tirosina cinasas.
US7863428B2 (en)	2002-12-27	2011-01-04	Tibotec Bvba	Fluorogenic enzyme substrates and methods of preparation
CN100506802C (zh) *	2004-06-04	2009-07-01	中国科学院上海药物研究所	一类甲酰肽样受体-1调节剂、其制备方法和用途
AU2007303846B2 (en) *	2006-10-04	2011-03-10	Pfizer Products Inc.	Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
US8034815B2 (en)	2007-01-11	2011-10-11	Critical Outcome Technologies, Inc.	Compounds and method for treatment of cancer
US7879802B2 (en)	2007-06-04	2011-02-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101429166B (zh) *	2007-11-07	2013-08-21	上海特化医药科技有限公司	喹唑啉酮衍生物及其制备方法和用途
EP2225226B1 (fr)	2007-12-26	2016-08-17	Critical Outcome Technologies, Inc.	Composés et leur utilisation dans un procédé pour le traitement du cancer
EP3239170B1 (fr)	2008-06-04	2019-03-20	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
CA2730890C (fr)	2008-07-17	2018-05-15	Critical Outcome Technologies Inc.	Composes inhibiteurs et procedes de traitement du cancer
CA2745694C (fr)	2008-12-03	2018-03-27	Synergy Pharmaceuticals, Inc.	Formulations d'agonistes de guanylate cyclase c et methode d'utilisation
EP3235818A3 (fr)	2010-04-01	2018-03-14	Critical Outcome Technologies, Inc.	Composés pour le traitement du vih
EP2621509A4 (fr)	2010-09-15	2016-08-03	Synergy Pharmaceuticals Inc	Préparations d'agonistes du guanylate cyclase-c et méthodes d'utilisation
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) *	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
EP3097088A4 (fr) *	2014-01-23	2017-10-04	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Dérivés de l'icariine
ES2749433T3 (es)	2014-06-23	2020-03-20	Celgene Corp	Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
CN110590769B (zh) *	2019-06-13	2021-09-24	中山大学	一对喹唑啉酮生物碱对映体及其制备方法和应用
WO2024026424A1 (fr) *	2022-07-27	2024-02-01	Black Diamond Therapeutics, Inc.	Dérivés de quinazolinone et utilisations associées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3169129A (en) *	1963-05-10	1965-02-09	American Cyanamid Co	2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
US4431440A (en) *	1981-02-20	1984-02-14	American Cyanamid Company	Method to alter or control the development and/or the life cycle of various plant species
GB9126260D0 (en) *	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
US5294612A (en) *	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

1995
- 1995-01-19 DE DE19501481A patent/DE19501481A1/de not_active Withdrawn
- 1995-12-26 IN IN2408DE1995 patent/IN184956B/en unknown
1996
- 1996-01-05 HR HR19501481.2A patent/HRP960004A2/hr not_active Application Discontinuation
- 1996-01-08 EP EP96100154A patent/EP0722937A1/fr not_active Withdrawn
- 1996-01-11 US US08/584,865 patent/US5721238A/en not_active Expired - Fee Related
- 1996-01-12 YU YU1496A patent/YU1496A/sh unknown
- 1996-01-15 TR TR96/00029A patent/TR199600029A2/xx unknown
- 1996-01-15 AU AU40980/96A patent/AU704102B2/en not_active Ceased
- 1996-01-16 CA CA002167345A patent/CA2167345A1/fr not_active Abandoned
- 1996-01-16 IL IL11677096A patent/IL116770A/xx active IP Right Grant
- 1996-01-16 NZ NZ280831A patent/NZ280831A/en unknown
- 1996-01-16 RO RO96-00077A patent/RO117451B1/ro unknown
- 1996-01-17 FI FI960227A patent/FI960227A/fi unknown
- 1996-01-17 JP JP8022973A patent/JPH08253457A/ja active Pending
- 1996-01-17 PL PL96312352A patent/PL312352A1/xx unknown
- 1996-01-17 SG SG1996000263A patent/SG34377A1/en unknown
- 1996-01-18 NO NO960222A patent/NO307513B1/no unknown
- 1996-01-18 BR BR9600148A patent/BR9600148A/pt active Search and Examination
- 1996-01-18 ZA ZA96397A patent/ZA96397B/xx unknown
- 1996-01-18 EE EE9600019A patent/EE9600019A/xx unknown
- 1996-01-18 BG BG100293A patent/BG100293A/xx unknown
- 1996-01-18 RU RU96100854/04A patent/RU2158733C2/ru active
- 1996-01-18 KR KR1019960001004A patent/KR960029325A/ko not_active Application Discontinuation
- 1996-01-18 SK SK77-96A patent/SK7796A3/sk unknown
- 1996-01-18 CZ CZ96167A patent/CZ16796A3/cs unknown
- 1996-01-18 MA MA24135A patent/MA23780A1/fr unknown
- 1996-01-19 PE PE1996000044A patent/PE66696A1/es not_active Application Discontinuation
- 1996-01-19 AR ARP960101087A patent/AR006738A1/es unknown
- 1996-01-19 SV SV1996000005A patent/SV1996000005A/es unknown
- 1996-01-19 CO CO96002168A patent/CO4700522A1/es unknown
- 1996-01-19 CN CN96101906A patent/CN1134417A/zh active Pending
- 1996-01-19 HU HU9600114A patent/HUP9600114A3/hu unknown

Also Published As

Publication number	Publication date
BR9600148A (pt)	1998-01-06
SG34377A1 (en)	1996-12-06
DE19501481A1 (de)	1996-07-25
IL116770A (en)	2000-08-31
AR006738A1 (es)	1999-09-29
US5721238A (en)	1998-02-24
CN1134417A (zh)	1996-10-30
JPH08253457A (ja)	1996-10-01
EE9600019A (et)	1996-08-15
NO960222D0 (no)	1996-01-18
SV1996000005A (es)	1997-03-11
KR960029325A (ko)	1996-08-17
PE66696A1 (es)	1997-03-09
CZ16796A3 (en)	1996-08-14
YU1496A (sh)	1998-09-18
HUP9600114A2 (en)	1996-12-30
FI960227A (fi)	1996-07-20
RO117451B1 (ro)	2002-03-29
AU704102B2 (en)	1999-04-15
PL312352A1 (en)	1996-07-22
CA2167345A1 (fr)	1996-07-20
RU2158733C2 (ru)	2000-11-10
NO960222L (no)	1996-07-22
HUP9600114A3 (en)	2000-03-28
IL116770A0 (en)	1996-05-14
TR199600029A2 (tr)	1996-08-21
NZ280831A (en)	1996-10-28
NO307513B1 (no)	2000-04-17
IN184956B (fr)	2000-10-07
AU4098096A (en)	1996-07-25
HU9600114D0 (en)	1996-03-28
SK7796A3 (en)	1996-08-07
CO4700522A1 (es)	1998-12-29
ZA96397B (en)	1996-08-28
FI960227A0 (fi)	1996-01-17
BG100293A (en)	1996-07-31
EP0722937A1 (fr)	1996-07-24
HRP960004A2 (en)	1998-02-28

Publication	Publication Date	Title
MA23780A1 (fr)	1996-10-01	Quinazolinones 2, 8 disubstitues
TR199600265A1 (tr)	1997-03-21	Kinazolin türevleri.
DK0823900T3 (da)	2001-04-02	Quinazolinderivater
NO2006016I1 (no)	2006-11-27	7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
PT993456E (pt)	2005-01-31	4,5-diaril-imidazoles 2-substituidos
DE69636353D1 (de)	2006-08-24	Datenübetragungsvorrichtung.
PT901487E (pt)	2003-08-29	4(3h)-quinazolinonas 2,3,6-trissubstituidas
DK0771789T3 (da)	2000-06-13	1 alpha, 26-dihydroxy-D-homo-vitamin D3
FI950715A0 (fi)	1995-02-17	Ytmikromekanisk, symmetrisk tryckskillnadsgivare
BR9506532A (pt)	1997-09-16	1,2,3,4,-Tetraidro-5-Nitro-Pirimidinas substituidas
BR9609884A (pt)	1999-03-23	N-aril- 1,2,4-triazolin-5-onas
NO985335D0 (no)	1998-11-16	2,4-Diaminopyrimidinderivater
DE69618634D1 (de)	2002-02-28	1,4-benzodioxin-derivate
DK0874814T3 (da)	2003-09-22	25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
DK1068200T3 (da)	2005-06-20	2,4,4-trisubstituerede-1,3-dioxolanfungicider
ID24047A (id)	2000-07-06	Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on
NO962931D0 (no)	1996-07-12	N,N-Dietyl-8,8-dipropyl-2-azaspiro[4,5Ådecan-2-propanamindimaleat
ES1032571Y (es)	1996-11-01	Gafa,
BR9508248A (pt)	1997-11-04	1,2,4,6-Tiatriazinas herbicidas
FR2724962B3 (fr)	1996-08-23	Tuile d'avant-toit sous-faitiere.
BR9610047A (pt)	1999-07-06	1,3,4-oxadiazolin-2-onas
FI952416A0 (fi)	1995-05-18	Distributionsanordning foer vaetska, speciellt tvaettvaetska foer vindrutor
FI950956A0 (fi)	1995-03-01	Luftkabel, saosom haengspiralkabel
IT1283187B1 (it)	1998-04-16	"elettrovalvola."
ES1038172Y (es)	1998-12-01	"caja-contenedor".